Ihr Kontakt

Elisabeth Harbich

Project Management Start-up Support

From science to venture

Are you a biomedical founding team ready to take your idea to the next level? Join our BioEntrepreneur Bootcamp 2026 – a biomedical start-up business training program in Munich designed to help you develop, validate, and accelerate your business concept.

Date: 3 February 2026 to 26 March 2026

Time:  Seven weeks, Tuesday-Thursday, full day

Location: Hybrid (virtually & BioM, Am Klopferspitz 19a, 82152 Martinsried-Planegg)

Costs: free for pre-seed teams from Bavaria

Pricing

  • Start-up teams from Bavaria 99 € 
  • Pre-seed / start-ups international 199 €

NO SHOW FEE:  for all teams 99 €

Application Period:  3 - 26 November 2025

Over seven weeks (sessions running from Tuesday to Thursday), participants engage in:

  • 9 on-site days in Munich
  • 12 full-day online sessions
  • Plus, off-site teamwork on validation, strategy, and pitching etc.

 

Who should apply?

Pre-seed biomedical teams with an innovative idea in:

  • Drugs and therapies 
  • Biotechnology diagnostics, prediction, or prognosis platforms
  • Drug discovery & development technologies platforms

What you gain:

  • Validate your concept with industry experts and potential partners
  • Strengthen your team and business roadmap
  • Learn about funding, IP, regulations, and deal-making essentials
  • Connect with mentors, investors, and pharma leaders

Why join?

  • Learn from top experts and gain hands-on expertise in business strategy, IP, financing, regulation, and partnering
  • Work with mentors throughout the program 
  • Pitch to an expert jury at the final Demo Day
  • Expand your stakeholder network 
  • Make sure your business model meets real market needs

Because every great idea deserves a great launchpad!


Mehr zum Thema

08.04.2026
Würzburger Start-up EMFRET Analytics treibt EMA601-Entwicklung gemeinsam mit Boehringer Ingelheim voran
Das Würzburger Biotech-Unternehmen EMFRET Analytics rückt mit seinem Antikörperprogramm EMA601 einen entscheidenden Schritt näher an die mögliche klinische Anwendung heran: Das Unternehmen…
Würzburger Start-up EMFRET Analytics treibt EMA601-Entwicklung gemeinsam mit Boehringer Ingelheim voran
07.04.2026
Gilead übernimmt Münchener Biotech-Unternehmen und m4-Award Gewinner Tubulis für bis zu 5 Milliarden US-Dollar
Das amerikanische Biopharmaunternehmen Gilead Sciences mit Sitz in Kalifornien übernimmt das Münchner Biotechnologieunternehmen Tubulis und baut damit seine Onkologie-Pipeline gezielt aus. Im…
Gilead übernimmt Münchener Biotech-Unternehmen und m<sup>4</sup>-Award Gewinner Tubulis für bis zu 5 Milliarden US-Dollar
25.03.2026
BayOConnect 2026: Agenda Expanded with New Sessions, Speakers and Perspectives – Registration Now Open for Europe’s Leading Biotech Forum
BayOConnect 2026 on 30 June - 1 July 2026 in Munich highlights what truly drives growth in biotechnology: Europe as a competitive innovation hub, capital turning innovation into scale, and…
BayOConnect 2026: Agenda Expanded with New Sessions, Speakers and Perspectives – Registration Now Open for Europe’s Leading Biotech Forum